We can’t show the full text here under this license. Use the link below to read it at the source.
Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy
Link Between Semaglutide or Tirzepatide Treatment and Remaining Stomach Contents That May Risk Upper Endoscopy
AI simplified
Abstract
Among 144 patients, 11 taking semaglutide or tirzepatide for over six months had residual gastric content during esophagogastroduodenoscopy.
- A significant association was found between GLP-1 usage for more than six months and the presence of residual gastric content (p<0.001).
- Of the 12 patients on long-term GLP-1 therapy, 91.7% exhibited residual gastric content.
- No residual gastric content was observed in the 132 patients who did not meet the inclusion criteria.
- A moderate positive association was noted between residual gastric content and age.
- A weak negative association was identified between residual gastric content and body mass index (BMI).
- There were no procedure-related complications, and all patients were discharged on the same day.
AI simplified